{"id":"teclistamab-tec","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4594505","moleculeType":"Antibody"},"_dailymed":{"setId":"54e0f974-ccee-44ea-9254-40e9883cee1e","title":"TECVAYLI (TECLISTAMAB) INJECTION [JANSSEN BIOTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teclistamab functions as a T-cell engager that bridges cytotoxic T lymphocytes to B-cell maturation antigen (BCMA)-expressing myeloma cells, bringing them into close proximity to facilitate T-cell activation and tumor cell killing. This bispecific mechanism allows for potent anti-myeloma activity by leveraging the patient's own immune system. The drug has demonstrated efficacy in relapsed/refractory multiple myeloma patients, including those heavily pretreated with other therapies.","oneSentence":"Teclistamab is a bispecific antibody that redirects T cells to kill multiple myeloma cells by simultaneously binding CD3 on T cells and BCMA on myeloma cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:49:36.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05243797","phase":"PHASE3","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2022-09-08","conditions":"Multiple Myeloma","enrollment":1594},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":"Multiple Myeloma","enrollment":587},{"nctId":"NCT06208150","phase":"PHASE3","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-01-22","conditions":"Multiple Myeloma","enrollment":795},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT05552222","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-25","conditions":"Multiple Myeloma","enrollment":1590},{"nctId":"NCT06100237","phase":"PHASE2","title":"Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)","status":"RECRUITING","sponsor":"Carl Ola Landgren, MD, PhD","startDate":"2023-12-04","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07099391","phase":"PHASE1, PHASE2","title":"A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-07-24","conditions":"Multiple Myeloma","enrollment":65},{"nctId":"NCT04586426","phase":"PHASE1, PHASE2","title":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-15","conditions":"Multiple Myeloma","enrollment":228},{"nctId":"NCT05231629","phase":"PHASE2","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-13","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT05572229","phase":"PHASE2","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":74},{"nctId":"NCT07107529","phase":"PHASE2","title":"Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.","status":"NOT_YET_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-10","conditions":"Multiple Myeloma (MM)","enrollment":150},{"nctId":"NCT07079423","phase":"PHASE2","title":"Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-06-28","conditions":"AL Amyloidosis","enrollment":35},{"nctId":"NCT06935162","phase":"PHASE2","title":"Teclistamab in Previously Treated AL Amyloidosis","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-21","conditions":"AL Amyloidosis","enrollment":30},{"nctId":"NCT06062537","phase":"","title":"Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2023-09-19","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT06699394","phase":"NA","title":"Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-03-29","conditions":"AL Amyloidosis","enrollment":20},{"nctId":"NCT05849610","phase":"PHASE2","title":"Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-09-21","conditions":"High-Risk de Novo Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-64007957"],"phase":"marketed","status":"active","brandName":"Teclistamab (Tec)","genericName":"Teclistamab (Tec)","companyName":"University of Heidelberg Medical Center","companyId":"university-of-heidelberg-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teclistamab is a bispecific antibody that redirects T cells to kill multiple myeloma cells by simultaneously binding CD3 on T cells and BCMA on myeloma cells. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}